Keytruda and Hepatic encephalopathy - a phase IV clinical study of FDA data

Summary:

Hepatic encephalopathy is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lenvima, and have Insomnia.

The phase IV clinical study analyzes which people have Hepatic encephalopathy when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Hepatic encephalopathy?

Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure) is found to be associated with 918 drugs and 1,259 conditions by eHealthMe. Check the latest studies of Hepatic encephalopathy.

On Jul, 02, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 32 people (0.06%) have Hepatic encephalopathy.

Could Keytruda cause Hepatic encephalopathy?

Among these 32 people:

How long have people been on Keytruda when they have Hepatic encephalopathy? *

What is the gender of people who have Hepatic encephalopathy when taking Keytruda? *

female: 34.38 %
male: 65.62 %

What is the age of people who have Hepatic encephalopathy when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Hepatic encephalopathy? *

Hepatic Failure (liver failure): 6 people, 18.75%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 5 people, 15.62%
Hepatitis Fulminant (life-threatening condition defined by significantly impaired liver function): 5 people, 15.62%
Drug-Induced Liver Injury (diseases of the liver that are caused by physician-prescribed medications): 4 people, 12.50%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 9.38%
Pseudomembranous Colitis (antibiotic-associated diarrhoea (aad), is an infection of the colon): 3 people, 9.38%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 3 people, 9.38%
Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 3 people, 9.38%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 3 people, 9.38%
Hepatic Atrophy (liver is decreased in size): 3 people, 9.38%

What are the existing conditions these people have? *

Insomnia (sleeplessness): 6 people, 18.75%
Renal Cell Carcinoma Stage Iv (stage iv renal cell cancer have cancer that has spread to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes): 5 people, 15.62%
Endometrial Cancer: 5 people, 15.62%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 4 people, 12.50%
Lung Squamous Cell Carcinoma Stage Iv (the lung cancer has spread to the other lung, and/or to lymph nodes, fluid around the lungs or heart, and/or other places in the body, such as the brain, liver, adrenal glands, kidneys, or bones): 3 people, 9.38%
Pain: 3 people, 9.38%
Hyperkalemia (damage to or disease of the kidney): 3 people, 9.38%
Constipation: 3 people, 9.38%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 6.25%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Hepatic encephalopathy?

- Check whether Hepatic encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (918 drugs)

Browse all the conditions that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (1,259 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.